1. O-005Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial. (2nd July 2019) Authors: Harding, J; Cleary, J; Shapiro, G; Braña, I; Moreno, V; Quinn, D; Borad, M; Loi, S; Spanggaard, I; Stemmer, S; Dujka, M; Cutler, R; Xu, F; Eli, L; Macia, S; Lalani, A; Bryce, R; Bernstam, F Meric; Solit, D; Hyman, D Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 422PFirst-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies. (23rd October 2018) Authors: Lorusso, P; Chawla, S P; Bendell, J; Shields, A F; Shapiro, G; Rajagopalan, P; Cyris, C; Bruns, I; Mei, J; Souza, F; Rasco, D; Eder, J P; Tolcher, A W Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗